Join
Live feed
·
INSIDERFilingvia Quantisnow
Adverum Biotechnologies Inc. logo

CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 8,125 shares, increasing direct ownership by 124% to 14,692 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ADVM· Adverum Biotechnologies Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADVM (Adverum Biotechnologies Inc.) and more on Quantisnow.